Yahoo
    Stockholm - Delayed Quote SEK

    BioInvent International AB (publ) (BINV.ST)

    5.43 -0.28 (-4.90%)
    At close: October 30 at 12:59:37 PM GMT+1
    BINV.ST Q3 2026 earnings call
    Replay the call for the latest insights.
    Loading Chart for BINV.ST
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Invitation to Presentation of BioInvent's Interim Report January - September 2026

    Invitation to Presentation of BioInvent's Interim Report January - September 2026
    ACCESS Newswire 4d ago
    BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

    BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
    ACCESS Newswire 7d ago
    BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

    BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026
    ACCESS Newswire 12d ago
    BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

    BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research
    ACCESS Newswire 16d ago
    BioInvent International AB Announces that its CFO will Retire in 2027

    BioInvent International AB Announces that its CFO will Retire in 2027
    ACCESS Newswire 19d ago
    BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

    BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research
    ACCESS Newswire 2mo ago
    BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

    BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
    ACCESS Newswire 2mo ago
    BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

    BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
    ACCESS Newswire 3mo ago
    BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

    BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
    ACCESS Newswire 3mo ago
    BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

    BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
    ACCESS Newswire 4mo ago
    Resolutions at BioInvent's Annual General Meeting 2026

    Resolutions at BioInvent's Annual General Meeting 2026
    ACCESS Newswire 5mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: